Skip to content
Article Rich – Lifestyle
Author:
Bicara Therapeutics Inc.
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
May 22, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 21, 2026
Bicara Therapeutics to Report First Quarter 2026 Financial Results and Business Updates on May 11, 2026, at 8:30 AM ET
May 4, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
April 3, 2026
Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 30, 2026
Bicara Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Business Updates on March 30, 2026, at 8:30 AM ET
March 23, 2026
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
March 6, 2026
Bicara Therapeutics Announces Closing of Oversubscribed Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 5, 2026
Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
March 4, 2026
Bicara Therapeutics Announces Proposed Public Offering of Common Stock
March 4, 2026